Novo Nordisk | NVO - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
ANI Pharmaceuticals USD 40.22M 8.74M 2026-03
Aurora Cannabis CAD 11.41M 12.99M 2026-03
Bausch Health Companies USD 348M 1.7B 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Canopy Growth CAD -157.96M 95.71M 2026-03
Corcept Therapeutics USD -44.72M 54.62M 2026-03
Drreddys Laboratories INR 2B 13.43B 2026-03
Eli Lilly USD 8.85B 583.8M 2026-03
GlaxoSmithKline GBP 2.68B 532M 2026-06
Merck USD -3.53B 6.95B 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Novartis USD 4.27B 430M 2026-06
Novo Nordisk DKK 33.8B 3.23B 2025-06
Novo Nordisk DKK 62.17B 36.66B 2026-03
Pacira USD 5M 4.43M 2026-03
Perrigo USD 105.4M 513.9M 2026-06
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 64.77M 2.96M 2026-03
Sanofi EUR 837M 1.17B 2026-06
Supernus Pharmaceuticals USD -57.65M 51.7M 2026-06
Zoetis USD 758M 3M 2026-03